NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Lumping NWBO 331 patients together in DCVax-L trial. All patients received SOC and or DCVax-L. 331 in trial with 2 year survival 90 patients = 27.19%. American Brian Tumor Association has 2 year survival rate of 30% for gpm patients.Not seeing any gains here. Comments anyone?

Your math is flawed. You can not compute MOS (or 2 year) by looking at the number alive..
A reasonable estimate for this trial is that the blended median is up over 20 months. The 2 year OS (still blended) is probably around 40-45% (I do not have my model around where I can check this, but should be about right for it).

So yes, that would be a gain. And one might reasonably presume "everybody is living longer".

But what that means is a far more difficult question, and one that will get us nowhere,